Telix and Xiel Sign U.K. and Ireland Distribution Agreement
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Development of Glioblastoma Therapy Program
- Radiopharmaceutical Production Facility Buildout Commences
- ZIRCON Phase 3 Imaging Study Completes Targets Enrolment
- Cancellation of Share Purchase Plan
- 2021 Full Year Results Presentation
Later from Telix Pharmaceuticals
- FDA Orphan Drug Designation for Bone Marrow Conditioning
- Commercial Launch - Illuccix Now Available to Order in US
- Telix, GMS & Monash Awarded $23 million Federal Funding
- Telix Enters Licence Agreement with Lilly for Olaratumab
- ProstACT TARGET Phase II Study Ethics Approval
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals